comprehensive -WSS

comprehensive

author：knowledge 2025-09-27 20:16:32 Page View：7428

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA advisers vote against ALS treatment from BrainStorm
Next article： Anesthesiologist group: stop taking Ozempic before surgery

knowledge

Medical leaders decry Supreme Court decision on affirmative action

STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

Congress considering partial increase for doctor pay in Medicare

Congressisdebatingincreasingdoctors'Medicarepay,butnotbringingituptolastyear'slevels.AlexWong/GettyI

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

DarronCummings/APEliLillysaidFridaythatitwillacquireDermira,asmallbiotechdevelopingdrugsforchronicsk

comprehensive

explore

knowledge

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline